Annovis Bio, Inc. (ANVS)
After hours:
| Previous Close | 5.39 |
| Open | 5.49 |
| Bid | 0.00 x 1400 |
| Ask | 0.00 x 800 |
| Day's Range | 5.20 - 5.56 |
| 52 Week Range | 4.86 - 22.49 |
| Volume | |
| Avg. Volume | 462,154 |
| Market Cap | 58.965M |
| Beta (5Y Monthly) | 1.59 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -6.23 |
| Earnings Date | May 09, 2024 - May 13, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 35.25 |
ZacksApellis' (APLS) Q1 Earnings Match Estimates, Revenues Beat
Apellis (APLS) reports first-quarter 2024 results, wherein earnings match the Zacks Consensus Estimate and revenues beat the same, driven by strong sales of Syfovre.
GlobeNewswireAnnovis Bio CEO Maria Maccecchini Issues Letter to Stockholders
MALVERN, Pa., May 06, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, announced that Maria Maccecchini, Founder, President, and CEO of Annovis, issued a letter to stockholders providing a review of Phase II/III data from its Alzheimer’s study and sharing next steps. Dear Friends, The last few days have been very difficult. I received a lot of emails and phone ca
ZacksBlueprint (BPMC) Q1 Earnings and Revenues Beat, Stock Rises
Blueprint (BPMC) gains from better-than-expected first-quarter 2024 results, driven by robust Ayvakit sales growth. The company raises its revenue guidance for 2024.
